In this study, we use pretreatment MRI and 64Cu-DT PET-CT to predict response at surgery to the combination of cytotoxic chemotherapy with the humanized monoclonal antibodies, trastuzumab and pertuzumab, in women with locally advanced HER2 + breast cancer (clinical trial NCT02827877). The gene discussed is ERBB2; the disease is breast cancer.